目的探讨食管鳞状细胞癌中DNA结合抑制蛋白-3(inhibitors of DNA binding 3,ID-3)的表达及临床意义。方法应用免疫组化SP法对109例食管鳞癌组织、40例切缘正常组织进行ID-3免疫组化染色,检测癌组织、正常食管黏膜组织中ID-3的表达,并分...目的探讨食管鳞状细胞癌中DNA结合抑制蛋白-3(inhibitors of DNA binding 3,ID-3)的表达及临床意义。方法应用免疫组化SP法对109例食管鳞癌组织、40例切缘正常组织进行ID-3免疫组化染色,检测癌组织、正常食管黏膜组织中ID-3的表达,并分析ID-3的表达与食管鳞癌临床病理特征的关系。结果食管鳞癌组织中ID-3蛋白的表达显著高于切缘正常组织(P<0.01),ID-3蛋白表达与肿瘤分化呈正相关(P<0.01),ID-3蛋白表达与患者的年龄、性别、浸润深度及是否伴淋巴结转移均无关。结论 ID-3高表达可能是食管鳞癌的一个重要的分子学改变,可能在食管鳞癌的发生、发展中起重要作用。展开更多
A simple analytical high-performance liquid chromatography （HPLC） method was applied for the en- antiomeric excess determination of esomeprazole （（S）-OME）, the enantiopure active ingredient con- tained in drug p...A simple analytical high-performance liquid chromatography （HPLC） method was applied for the en- antiomeric excess determination of esomeprazole （（S）-OME）, the enantiopure active ingredient con- tained in drug products, in the presence of its potential organic impurities A-E. The enantioselective separation was accomplished on the immobilized-type Chiralpak ID-3 chiral stationary phase （CSP） under reversed-phase conditions. The results were evaluated and compared with those obtained by the official enantioselective method of European Pharmacopoeia used as the reference for checking the enantiomeric excess of （S）-OME. It has been established that the use of the Chiralpak ID-3 CSP allows the determination of the enantiomeric purity of （S）-OME without any interference coming from its chiral and achiral related substances. The analytical procedure of the drug regulatory agencies based on the AGP CSP suffered instead from poor specificity due to overlap of the peaks pertinent to the achiral impurity A and the chiral impurity （R）-OME （impurity F）.展开更多
文摘目的探讨食管鳞状细胞癌中DNA结合抑制蛋白-3(inhibitors of DNA binding 3,ID-3)的表达及临床意义。方法应用免疫组化SP法对109例食管鳞癌组织、40例切缘正常组织进行ID-3免疫组化染色,检测癌组织、正常食管黏膜组织中ID-3的表达,并分析ID-3的表达与食管鳞癌临床病理特征的关系。结果食管鳞癌组织中ID-3蛋白的表达显著高于切缘正常组织(P<0.01),ID-3蛋白表达与肿瘤分化呈正相关(P<0.01),ID-3蛋白表达与患者的年龄、性别、浸润深度及是否伴淋巴结转移均无关。结论 ID-3高表达可能是食管鳞癌的一个重要的分子学改变,可能在食管鳞癌的发生、发展中起重要作用。
文摘A simple analytical high-performance liquid chromatography （HPLC） method was applied for the en- antiomeric excess determination of esomeprazole （（S）-OME）, the enantiopure active ingredient con- tained in drug products, in the presence of its potential organic impurities A-E. The enantioselective separation was accomplished on the immobilized-type Chiralpak ID-3 chiral stationary phase （CSP） under reversed-phase conditions. The results were evaluated and compared with those obtained by the official enantioselective method of European Pharmacopoeia used as the reference for checking the enantiomeric excess of （S）-OME. It has been established that the use of the Chiralpak ID-3 CSP allows the determination of the enantiomeric purity of （S）-OME without any interference coming from its chiral and achiral related substances. The analytical procedure of the drug regulatory agencies based on the AGP CSP suffered instead from poor specificity due to overlap of the peaks pertinent to the achiral impurity A and the chiral impurity （R）-OME （impurity F）.
